145 related articles for article (PubMed ID: 38512893)
21. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.
Voican CS; Mir O; Loulergue P; Dhooge M; Brezault C; Dréanic J; Chaussade S; Pol S; Coriat R
Ann Oncol; 2016 Dec; 27(12):2172-2184. PubMed ID: 27803003
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours.
Ling WH; Soe PP; Pang AS; Lee SC
Br J Cancer; 2013 May; 108(10):1931-5. PubMed ID: 23652302
[TBL] [Abstract][Full Text] [Related]
24. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
25. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.
Elkady A; Aboulfotuh S; Ali EM; Sayed D; Abdel-Aziz NM; Ali AM; Murakami S; Iijima S; Tanaka Y
World J Gastroenterol; 2013 Oct; 19(37):6214-20. PubMed ID: 24115819
[TBL] [Abstract][Full Text] [Related]
26. Screening for viral hepatitis prior to rituximab chemotherapy.
Leonard AN; Love BL; Norris LB; Siddiqui SK; Wallam MN; Bennett CL
Ann Hematol; 2016 Jan; 95(1):27-33. PubMed ID: 26382277
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.
Lv JW; Chen YP; Huang XD; Zhou GQ; Chen L; Li WF; Tang LL; Mao YP; Guo Y; Xu RH; Ma J; Sun Y
Cancer; 2017 Sep; 123(18):3540-3549. PubMed ID: 28493307
[TBL] [Abstract][Full Text] [Related]
28. An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening.
Leung C; Tsoi E; Burns G; Sievert W
Oncologist; 2011; 16(5):579-84. PubMed ID: 21464465
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.
Hwang JP; Huang D; Vierling JM; Suarez-Almazor ME; Shih YT; Chavez-MacGregor M; Duan Z; Giordano SH; Hershman DL; Fisch MJ; Cantor SB
JCO Clin Cancer Inform; 2019 Mar; 3():1-12. PubMed ID: 30892921
[TBL] [Abstract][Full Text] [Related]
32. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
[TBL] [Abstract][Full Text] [Related]
33. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
34. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.
Hwang JP; Fisch MJ; Lok AS; Zhang H; Vierling JM; Suarez-Almazor ME
BMC Cancer; 2013 Nov; 13():534. PubMed ID: 24209764
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis.
Kawsar HI; Shahnewaz J; Gopalakrishna KV; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2012 Jun; 10(6):370-8. PubMed ID: 22895238
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases.
Hwang JP; Barbo AG; Perrillo RP
J Viral Hepat; 2015 Mar; 22(3):346-52. PubMed ID: 25220947
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
38. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.
Hwang JP; Suarez-Almazor ME; Cantor SB; Barbo A; Lin HY; Ahmed S; Chavez-MacGregor M; Donato-Santana C; Eng C; Ferrajoli A; Fisch MJ; McLaughlin P; Simon GR; Rondon G; Shpall EJ; Lok AS
Cancer; 2017 Sep; 123(17):3367-3376. PubMed ID: 28518219
[TBL] [Abstract][Full Text] [Related]
39. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.
Artz AS; Somerfield MR; Feld JJ; Giusti AF; Kramer BS; Sabichi AL; Zon RT; Wong SL
J Clin Oncol; 2010 Jul; 28(19):3199-202. PubMed ID: 20516452
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
Wu YT; Li X; Liu ZL; Xu Z; Dai W; Zhang K; Wu JS; Arshad B; Wu KN; Kong LQ
PLoS One; 2017; 12(6):e0179680. PubMed ID: 28640902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
